- Home
- LPRO vs ENLV Comparison
LPRO vs ENLV Comparison
Compare LPRO & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | ENLV |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 249.3M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | LPRO | ENLV |
|---|---|---|
| Price | $1.91 | $1.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $2.83 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 717.5K | 472.3K |
| Earning Date | 11-06-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,948,000.00 | N/A |
| Revenue This Year | $306.66 | N/A |
| Revenue Next Year | $7.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $0.66 |
| 52 Week High | $6.73 | $2.10 |
Technical Indicators
Market Signals| Indicator | LPRO | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 67.94 |
| Support Level | $1.93 | $0.92 |
| Resistance Level | $2.06 | $1.03 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 44.16 | 100.00 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.